BRAF V600 K mutation-positive melanoma
GPTKB entity
Statements (93)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:can_be_aggressive_in |
advanced stages
|
| gptkbp:can_be_screened_for |
early detection
|
| gptkbp:can_be_used_to |
resistance to treatment
|
| gptkbp:can_cause |
skin lesions
|
| gptkbp:can_detect |
biopsy
|
| gptkbp:can_develop_resistance_to |
targeted therapy
|
| gptkbp:can_lead_to |
metastasis
|
| gptkbp:diagnosis |
biopsy
dermatoscopy |
| gptkbp:exhibits |
itching
|
| gptkbp:genetic_studies |
BRAF V600 K
|
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600 K mutation-positive melanoma
|
| gptkbp:is_affected_by |
environmental factors
treatment adherence age |
| gptkbp:is_analyzed_in |
clinical research
pathology genetic counseling |
| gptkbp:is_associated_with |
gptkb:immunotherapy
targeted therapy tumor heterogeneity tumor microenvironment specific biomarkers poor prognosis tumor markers increased risk of recurrence increased tumor growth |
| gptkbp:is_characterized_by |
abnormal cell growth
abnormal BRAF protein |
| gptkbp:is_common_in |
Caucasians
younger adults advanced melanoma |
| gptkbp:is_considered |
treatment guidelines
a public health concern a significant health issue a complex disease aggressive cancer a serious health condition a subtype of melanoma |
| gptkbp:is_considered_as |
target for therapy
|
| gptkbp:is_evaluated_by |
imaging studies
clinical settings clinical assessments therapeutic studies |
| gptkbp:is_influenced_by |
lifestyle choices
|
| gptkbp:is_linked_to |
immune response
family history sun exposure genetic predisposition treatment outcomes poor prognosis increased mutation burden increased risk of recurrence |
| gptkbp:is_managed_by |
patient education
supportive care oncologists multidisciplinary care |
| gptkbp:is_monitored_by |
follow-up care
|
| gptkbp:is_more_aggressive_than |
BRAF wild-type melanoma
|
| gptkbp:is_often_discussed_in |
gptkb:literature
|
| gptkbp:is_often_investigated_in |
epidemiological studies
genomic studies |
| gptkbp:is_often_seen_in |
skin lesions
|
| gptkbp:is_part_of |
cancer research
precision medicine cancer genomics melanoma research melanoma classification melanoma treatment guidelines |
| gptkbp:is_recognized_by |
genetic testing
|
| gptkbp:is_related_to |
BRAF gene
|
| gptkbp:is_studied_in |
clinical trials
laboratory research pharmacogenomics |
| gptkbp:is_subject_to |
monitoring
ongoing research |
| gptkbp:is_tested_for |
genetic testing
|
| gptkbp:occurs_in |
gptkb:Skin
adults |
| gptkbp:treatment |
gptkb:dabrafenib
gptkb:immunotherapy gptkb:surgery combination therapy targeted therapies radiation therapy chemotherapy BRAF inhibitors novel therapies adjuvant therapy |
| gptkbp:bfsParent |
gptkb:Trametinib
gptkb:BRAF_V600_E_mutation-positive_melanoma |
| gptkbp:bfsLayer |
7
|